Pipelines
| Disease Area | Product | Modality | Indication | 2021 | 2022 (E) | 2023 (E) | 2024 (E) | 2025 (E) | 2026 (E) |
| Oncology | AMB302 | ADC | GBM, bladder | Late Discovery |
Pre-clinical |
Phase 1a |
|||
| AMB015 | ADC | Hematologic & solid tumors |
Late Discovery |
Pre-clinical |
Phase 1a |
||||
| AMB018 | mAb | Solid tumors | Late Discovery |
Pre-clinical |
Phase 1a |
||||
| Neurodeg enerative |
AMB011 | mAb | Dementia | Late Discovery |
Pre-clinical |
Phase 1a |
|||
| AMB001 | mAb | Brain diseases | Late Discovery |
Pre-clinical |
Phase 1a |
||||
| BBB crossing | AMB016 | bsAb | Brain diseases | Late Discovery |
Pre-clinical |
Phase 1a |
Oncology
- Late-Discovery
- Pre-Clinical
- Phase 1a
| Product | Modality | Indication |
|---|---|---|
| AMB302 | ADC | GBM, Bladder Cancer |
Undisclosed ADC program that utilizes AIMEDBIO’s proprietary antibody targeting a fusion protein in glioblastoma
| Product | Modality | Indication |
|---|---|---|
| AMB015 | ADC | Hematologic & solid tumors |
AMB015 is an undisclosed program that utilizes AIMEDBIO’s proprietary ADC platform technology, consisting of a novel payload with outstanding efficacy in glioblastoma.
| Product | Modality | Indication |
|---|---|---|
| AMB018 | mAb | Solid tumors |
AMB018 is a monoclonal antibody that targets and suppresses tumor-associated macrophages (TAM) present in solid tumors.
Neurodegenerative
- Late-Discovery
- Pre-Clinical
- Phase 1a
| Product | Modality | Indication |
|---|---|---|
| AMB011 | mAb | Dementia |
AMB011 is designed to treat neurodegenerative diseases by targeting a cell surface receptor expressed on myeloid-lineage cells.
| Product | Modality | Indication |
|---|---|---|
| AMB001 | mAb | Brain diseases |
AMB001 is designed to treat multiple sclerosis and neurodegenerative diseases by targeting a cell surface receptor expressed on microglia.
BBB Crossing
- Late-Discovery
- Pre-Clinical
- Phase 1a
| Product | Modality | Indication |
|---|---|---|
| AMB016 | bsAb | Brain diseases |
AMB016 is a bispecific antibody that is engineered to combine AIMEDBIO’s proprietary BBB penetrating platform with a CNS disease drug.
| AMB302 | AMB302 is an undisclosed ADC program that utilizes AIMEDBIO’s proprietary antibody targeting a fusion protein in glioblastoma. |
| AMB015 | AMB015 is an undisclosed program that utilizes AIMEDBIO’s proprietary ADC platform technology, consisting of a novel payload with outstanding efficacy in glioblastoma. |
| AMB018 | AMB018 is a monoclonal antibody that targets and suppresses tumor-associated macrophages (TAM) present in solid tumors. |
| AMB011 | AMB011 is designed to treat neurodegenerative diseases by targeting a cell surface receptor expressed on myeloid-lineage cells. |
| AMB001 | AMB001 is designed to treat multiple sclerosis and neurodegenerative diseases by targeting a cell surface receptor expressed on microglia. |
| AMB016 | AMB016 is a bispecific antibody that is engineered to combine AIMEDBIO’s proprietary BBB penetrating platform with a CNS disease drug. |
